Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
It’s not the splashy acquisition Sanofi was expected to make after pocketing more than $11 billion following the sale of a big chunk of partner Regeneron’s stock, but it’s a start. On Tuesday, the company signed a pact with China’s Alphamab Oncology to collaborate on a bispecific antibody focused on treating breast cancer.
The deal represents Sanofi’s ambitions in China, where skyrocketing rates of cancer have sparked the creation of biotech firms that have lured millions in venture funding and public listings.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.